Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment

被引：0
|
作者：
Yamin Shu
Lei Wang
Yiling Ding
Qilin Zhang
机构：
[1] Huazhong University of Science and Technology,Department of Pharmacy, Tongji Hospital, Tongji Medical College
[2] Chongqing University Central Hospital,Pharmacy Department, Chongqing Emergency Medical Center
[3] University of Tokyo,Graduate School of Pharmaceutical Sciences
[4] Huazhong University of Science and Technology,Department of Pharmacy, Union Hospital, Tongji Medical College
来源：
Drug Safety | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：881 / 895
页数：14
相关论文
共 50 条
  • [1] Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment
    Shu, Yamin
    Wang, Lei
    Ding, Yiling
    Zhang, Qilin
    [J]. DRUG SAFETY, 2023, 46 (09) : 881 - 895
  • [2] Post-marketing safety concerns with abrocitinib: a real-world pharmacovigilance analysis of the FDA adverse event reporting system
    Zhu, Zhou
    Liu, Mingjuan
    Zhang, Hanlin
    Zheng, Heyi
    Li, Jun
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
  • [3] Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System
    Liu, Yan-xin
    Dong, Chang-jiang
    He, Xu-cheng
    Shu, Ya-min
    Wu, Pan
    Zou, Jian
    [J]. JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2022, 25 : 377 - 390
  • [4] Post-marketing safety of finerenone: a disproportionality analysis of the FDA adverse event reporting system
    Jin, Yiyi
    Fan, Miao
    Zheng, Xiaomeng
    Zhu, Suyan
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
  • [5] Post-marketing safety concerns with palbociclib: a disproportionality analysis of the FDA adverse event reporting system
    Cheng, Qian
    Shi, Xuan
    Zhao, Yazheng
    Zou, Shupeng
    Sun, Minghui
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024, 23 (05) : 637 - 648
  • [6] Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
    Shu, Yamin
    Ding, Yufeng
    Liu, Yanxin
    Wu, Pan
    He, Xucheng
    Zhang, Qilin
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [7] A real-world disproportionality analysis of semaglutide: Post-marketing pharmacovigilance data
    Du, Yikuan
    Zhang, Mengting
    Wang, Zhenjie
    Hu, Mianda
    Xie, Dongxia
    Wang, Xiuzhu
    Guo, Zhuoming
    Zhu, Jinfeng
    Zhang, Weichui
    Luo, Ziyi
    Yang, Chun
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2024,
  • [8] A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data
    Zhang, Qilin
    Ding, Yiling
    Shu, Yamin
    Chen, Jing
    [J]. BMC CANCER, 2023, 23 (01)
  • [9] Post-marketing safety concerns with elagolix: a disproportionality analysis of the FDA adverse event reporting system
    Chang, En
    Shi, Yong-Fang
    Liu, Jin-Feng
    Wei, Wei
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
  • [10] Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting system
    Xia, Chunyong
    Liu, Zhijing
    Liu, Jie
    Lin, Li
    Chen, Maohua
    [J]. INVESTIGATIONAL NEW DRUGS, 2024,
12345